Abstracts tagged "Outcome measures"

Abstract Number: 763 • 2013 ACR/ARHP Annual Meeting
The Risk Of Myocardial Infarction In Systemic Sclerosis: A Population-Based Cohort Study
Iman Hemmati¹, Hyon K. Choi^2,3, Kamran Shojania^3,4, Eric C. Sayre³ and J. Antonio Avina-Zubieta^3,5, ¹Deparment of Medicine and Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: An increased risk of premature atherosclerosis has been well described in patients with rheumatoid arthritis and systemic lupus erythematosus. However, there is limited data…
Abstract Number: 2245 • 2013 ACR/ARHP Annual Meeting
Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Paul R. Fortin³, George A. Tomlinson⁴ and Claire Bombardier^5,6, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Division of rheumatology and Department of Health Policy, Management, and Evaluation, University Health Network, Toronto, ON, Canada
Background/Purpose: Patient reported outcome measures (PROM) are used in routine practice for assessment of disease activity. They have been shown to correlate well with other…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 2247 • 2013 ACR/ARHP Annual Meeting
Response To a Sleep Query On The Multi-Dimensional Health Assessment Questionnaire (MDHAQ) Is Related To Levels Of Disease Activity
Martin J. Bergman^1,2, Sapna Sangani³, Isabel Castrejón⁴ and Theodore Pincus⁴, ¹Medicine, Drexel University College of Medicine, Philadelphia, PA, ²Taylor Hospital, Ridley Park, PA, ³Medicine, Mercy Catholic Medical Center, Lansdowne, PA, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with rheumatoid arthritis (RA) often report fatigue, but a possible impact of disease on sleep and/or on disease activity are poorly characterized. We…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 2135 • 2013 ACR/ARHP Annual Meeting
Musculoskeletal Pain Explains Differences In Function At Time Of Surgery In Black TKR and THR Patients
Anthony Porter¹, Wenjun Li², Leslie R. Harrold¹, Milagros Rosal³, Philip Noble⁴, David Ayers², Patricia D. Franklin² and Jeroan Allison⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ³Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA, ⁴Baylor College of Medicine, Houston, TX, ⁵Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA
Background/Purpose: The existence of racial disparities in total knee (TKR) and total hip (THR) replacement outcomes is well established but not well understood. The burden…
Abstract Number: 429 • 2013 ACR/ARHP Annual Meeting
Sustained Clinical Efficacy After Multiple Courses of Rituximab in Rheumatoid Arthritis Patients With Inadequate Response to Tumour Necrosis Factor Inhibitors: 2-Year Data From the Repeat (Repeated Courses in Routine Clinical Practice) Study
Catalin Codreanu¹, Ioan Ancuta² and Ruxandra Ionescu³, ¹Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, ²“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ³Internal Medicine, Clinic Hospital Sf. Maria, Bucharest, Romania
Background/Purpose: In the last decade, biologic therapy changed dramatically treatment options for rheumatoid arthritis (RA). However, a significant number of patients failed to maintain the…
Abstract Number: 2136 • 2013 ACR/ARHP Annual Meeting
Does Functional Gain and Pain Relief After TKR and THR Differ By Patient Obese Status?
Wenjun Li¹, Leslie R. Harrold², Jeroan Allison³, Courtland Lewis⁴, Thomas Bowen⁵, Patricia D. Franklin¹ and David Ayers¹, ¹Orthopedics and Physical Rehabilitation, University of Massachusetts Medical School, Worcester, MA, ²University of Massachusetts Medical School, Worcester, MA, ³Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, ⁴Hartford Hospital, Hartford, CT, ⁵Geisinger, Danville, PA
Background/Purpose: Obesity is an important predictor of functional status and pain after total knee (TKR) and total hip (THR) replacement. However, variations in pre-post TKR…
Abstract Number: 314 • 2013 ACR/ARHP Annual Meeting
Impact Of Low Infliximab Dose Regimen On Treatment Response and Drug Survival In 462 Patients With Psoriatic Arthritis. Results From The Nationwide Registries Danbio and Icebio
Bente Glintborg^1,2, Bjorn Gudbjornsson^3,4, Niels Steen Krogh⁵, Emina Omerovic², Natalia Manilo⁶, Mette Holland-Fischer⁷, Hanne M. Lindegaard⁸, Anne Gitte Loft⁹, Henrik Nordin¹⁰, Laura Johnsen¹¹, Sussi Flejsborg Oeftiger¹², Annette Hansen¹³, Claus Rasmussen¹⁴, Gerdur Grondal¹⁵, Árni Jón Geirsson¹⁶ and Merete Lund Hetland^1,2,17, ¹The Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup Hospital, Glostrup, Denmark, ³Department of Rheumatology, Center for Rheumatology Research (ICEBIO), Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland, ⁴Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ⁵ZiteLab ApS, Copenhagen, Denmark, ⁶Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁹Department of Rheumatology, Sygehus Lillebaelt, Vejle, Denmark, ¹⁰Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Denmark, ¹¹Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Denmark, ¹²Department of Rheumatology, Køge Hospital, Køge, East Timor, ¹³Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ¹⁴Vendsyssel Teaching Hospital/Aalborg University, Hjoerring, Denmark, ¹⁵Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁶Rheumatology, Department of Rheumatology, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland, ¹⁷Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark
Background/Purpose: International guidelines recommend that in psoriatic arthritis infliximab should be dosed with 5 mg/kg bodyweight every 8th week. Data on the use of lower…
Abstract Number: 1979 • 2013 ACR/ARHP Annual Meeting
Occupational Balance Questionnaire: From People’s Perspectives To A Patient Reported Outcome
Mona Dür¹, Gunter Steiner², Michaela Stoffer³, Alexandra Kautzky-Willer⁴, Veronika Fialka-Moser⁵, Clemens Dejaco⁶, Birgit Prodinger⁷, Alexa Binder⁸, Josef S. Smolen^9,10 and Tanja A. Stamm¹¹, ¹Internal Medicine III Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Internal Medicine III, division of rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Internal Medicine III, Division of Diabetology, Medical University of Vienna, Vienna, Austria, ⁵Physical Medicine and Rehabilitation, Medical University of Vienna, Vienna, Austria, ⁶Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, ⁷ICF Research Branch, Swiss Paraplegic Group, Nottwil, Switzerland, Notwill, Switzerland, ⁸Occupational therapy, Hospital Goettlicher Heiland, Vienna, Austria, ⁹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹⁰Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ¹¹Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Occupational balance is one of the foundations on which occupational therapy is based. Occupational balance is defined diversely and mainly derived from the perspective…
Abstract Number: 191 • 2013 ACR/ARHP Annual Meeting
Does Specific Joint Involvement In Rheumatoid Arthritis Patients Predict Patient Reported Outcomes? Implications For Clinical Practice
Regan Arendse¹, William G. Bensen², Andrew Chow³, Jude F. Rodrigues⁴, Sanjay Dixit⁵, Dalton E. Sholter⁶, Philip Baer⁷, Milton F. Baker⁸, Denis Choquette⁹, Isabelle Fortin¹⁰, Algis Jovaisas¹¹, Emmanouil Rampakakis¹², John S. Sampalis¹², Francois Nantel¹³, Susan M. Otawa¹⁴, May Shawi¹⁵ and Allen J. Lehman¹⁴, ¹University of Saskatchewan, Saskatoon, SK, Canada, ²Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ³University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁴Rheumatology, Windsor, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Rheumatology Associates, Edmonton, AB, Canada, ⁷Private Practice, Scarborough, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ¹⁰Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ¹¹Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹²JSS Medical Research, Montreal, QC, Canada, ¹³Janssen Inc., Toronto, ON, Canada, ¹⁴Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Assessment of functional (dis)ability in rheumatoid arthritis (RA) is subject to patient judgment when appraising their ability to do daily activities. The aim of…
Abstract Number: 1881 • 2013 ACR/ARHP Annual Meeting
HLA-DRB1 Rheumatoid Arthritis Susceptibility Amino Acids Define Haplotypes Associated With Radiological Outcome
Sebastien Viatte¹, Annie Yarwood², Buhm Han^3,4, Soumya Raychaudhuri³, Deborah P. M. Symmons⁵, Jane Worthington^6,7 and Anne Barton^8,9, ¹Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, ⁵Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, The University of Manchester and Rheumatoid Arthritis Consortium for Immunochip (RACI), International Consortium, United Kingdom, ⁷Arthritis Research UK Epidemiology Unit, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁸Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁹NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a systematic autoimmune disease caused by the interplay between environmental and genetic risk factors. The major genetic determinants of RA…
Abstract Number: 109 • 2013 ACR/ARHP Annual Meeting
Comparison Of Characteristics In Rheumatoid Arthritis Between International and National Databases In Europe: A Systematic Literature Review
E. Gvozdenovic¹, R. Koevoets¹, J. Langenhoff², C.F. Allaart¹ and R. Landewe³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: RA (Rheumatoid Arthritis) cohorts and registers are established for daily practice in clinical care. There are still differences between registries in disease activity and…
Abstract Number: 1791 • 2013 ACR/ARHP Annual Meeting
Reaching The Target Of Low Disease Activity At 6 Months Predicts Better Long-Term Functional Outcome In Patients With Early Rheumatoid Arthritis
Pooneh Akhavan¹, Bindee Kuriya², Edward C. Keystone^3,4, Juan Xiong⁵, Janet E. Pope⁶, Gilles Boire⁷, Diane Tin⁸, Boulos Haraoui⁹, Carol A. Hitchon¹⁰ and Vivian P. Bykerk^11,12, ¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ²Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, Canada, ⁵Mount Sinai Hospital, Toronto, ON, Canada, ⁶St Joseph Health Care, London, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ¹⁰Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ¹¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ¹²Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Current clinical practice guidelines recommend remission, and if not possible, low disease activity (LDA) as the treatment target in rheumatoid arthritis (RA). Patients should…
Abstract Number: 1473 • 2012 ACR/ARHP Annual Meeting
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Giuseppina Abignano¹, Giovanna Cuomo², Maya H. Buch³, William M. Rosenberg⁴, Gabriele Valentini⁵, Paul Emery⁶ and Francesco Del Galdo⁷, ¹Chapel Allerton Hospital Leeds Insitute of Molecular medicine, Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ⁴Centre for Hepatology - UCL, London, United Kingdom, ⁵Rheumatology/Int Med, Second University of Naples, Rheumatology Unit, Naples, Italy, ⁶Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and NIHR LMBRU, Leeds, United Kingdom, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: A recent large multicenter study has identified an algorithm, known as Enhanced Liver Fibrosis (ELF), by combining the serum concentrations of amino-terminal propeptide of procollagen type III (PIIINP),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.